FRENCH CAPITAL (Reuters) Nov 13 - Sanofi-Aventis said on Tuesday the European Authorization had endorsed the positive degree legal document of the European Medicines Assessment Business organization (EMEA) for its anti-obesity drug Acomplia (rimonabant) to include type 2 diabetes endeavour results into the European radioisotope.
The update is based on the results of the VOCAL domain, which showed rimonabant 20 mg significantly improved glycemic relation in newly diagnosed type 2 diabetic patients, the subject matter said.
The bailiwick also demonstrated that rimonabant 20 mg had additional benefits on cardio-metabolic risk factors beyond diabetes.
No comments:
Post a Comment